TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Our Big Problem Obesity is spreading—and eating away at America's economy and health. Theodore Dalrymple on how society can bite back. online.wsj.com |
17 High-Yielding Stocks Traded on the OTC Markets David Hunkar submits: I ran the stock screener for OTC stocks yielding more than 5% dividends and having market caps of at least $5B. The following 17 stocks met the above criteria: 1. Telstra Corporation Limited (TLSYY.PK) Current Dividend Yield: 9.40% Sector: Telecom AustraliaComplete Story » seekingalpha.com |
Cadus Corporation: Less a Company Than a Publicly Traded Checking Account - WSJ Greenbackd submits: In September last year I picked up a small position in Cadus Corporation (OTC: KDUS.OB). The idea was as follows: Cadus Corporation is an interesting play, but not without hairs on it. First, the good news: It’s trading at a discount to net cash with Carl Icahn disclosing an activist holding in 2002, and Moab Capital Partners disclosing an activist holding more recently. At its $1.51 close yesterday, the company has a market capitalization of $19.9M. The valuation is straight-forward. We estimate the net cash value to be around $20.6M or $1.57 per share and the liquidation value to be around $23.2M or $1.77 per share. The liquidation value excludes the potential value of federal and New York State and City net operating loss carry-forwards. It’s not a huge upside but it’s reasonably certain, and we think that’s a good thing in this market. The problem with the position is the catalyst. It’s a relatively tiny position for Icahn, so he’s got no real incentive to do anything with it. He’s been in the position since 2002, so he’s clearly in no hurry. That said, he’s not ignoring the position. He last updated his 13D filing in March this year, disclosing an increased 40% stake. He’s also got Moab Capital Partners to contend with. Moab holds 9.8% of the stock and says that it “has had good interaction with the CEO of Cadus, David Blitz, and feels comfortable that he will structure a transaction with an operating business that will generate significant long-term value for Cadus holders.” KDUS could end up being a classic value trap, but we think it’s worth a look at a discount to net cash, and two interested shareholders.Complete Story » seekingalpha.com |
Health Outlays Still Seen Rising The health-care overhaul enacted last spring won't significantly change national health spending over the next decade compared with projections before the law was passed. online.wsj.com |
J&J Is Faulted on Recall Timing Johnson & Johnson should have moved sooner to recall some Motrin pills that it discovered were defective in late 2008, a federal official said in prepared testimony. online.wsj.com |